evans blue has been researched along with bortezomib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Assereto, S; Bonetto, A; Bonuccelli, G; Bruno, C; Cilli, M; Gazzerro, E; Lisanti, MP; Minetti, C; Pistorio, A; Scarfì, S; Sotgia, F; Zara, F | 1 |
2 other study(ies) available for evans blue and bortezomib
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies.
Topics: Animals; Boronic Acids; Bortezomib; Disease Models, Animal; Dystroglycans; Evans Blue; Gene Expression Regulation; Glycoproteins; Mice; Mice, Inbred C57BL; Muscular Dystrophy, Duchenne; Mutation; Proteasome Inhibitors; Pyrazines; Sarcoglycans; Ubiquitin | 2010 |